ClinicalTrials.gov
ClinicalTrials.gov Menu

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03110380
Recruitment Status : Active, not recruiting
First Posted : April 12, 2017
Last Update Posted : August 24, 2018
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : November 2018
  Estimated Study Completion Date : December 2020